HTR5A and breast neoplasm: All three PDX-derived cell lines responded similarly to treatment with SB-699551 (Fig. 1d), suggesting that selective antagonists of 5-HT5A eliminate tumorsphere initiating cells in breast tumor cell lines and PDX-derived cell lines independent of their subtype.